Antirabies vaccines produced from infected brains of adult mammals have always had the potentiality of causing post-vaccinal paralysis or allergic encephalitis in man. Attempts in recent years either to remove the paralytic factor from brain-tissue vaccines or to use as the virus source infected tissue other than nervous tissue (e.g., chick embryos) have usually resulted in a substantial reduction of the specific antirabies potency.The authors' laboratory had previously developed a vaccine made from infected suckling-mouse brains in which the virus was inactivated by ultraviolet irradiation. This vaccine was found highly potent in animal tests and low in organ-specific antigens. Others have found the brains of newborn mammals to be free of the allergic encephalitic factor. The studies reported in this paper show that the antirabies antibody responses to a 14-dose course of this suckling-mouse-brain vaccine in children are at a high level even when the vaccine is used at a 1% tissue concentration. There was no evidence of deleterious reactions to this treatment in 31 children.It is concluded that these results justify a long-term trial of this vaccine for antirabies prophylaxis in man.